IPO SnapShot

MURAE ORGANISOR LTD.

IPODATE
Jun 21, 2019 TO Jun 26, 2019
LISTINGDATE
7/4/2019 12:00:00 AM
APPLY NOW
FACEVALUE
₹ 2

per share

ISSUESIZE
₹ 6.6528 Cr
PRICEBAND
₹ 36

per share

MARKETLOT
3000

shares

OBJECTIVE

1. To meet Working Capital requirements2. General Corporate Purpose3. To meet issue expenses

DON'T HAVE A DEMAT ACCOUNT

OPENDEMAT ACCOUNTAND START YOURINVESTMENTJOURNEY WITH US

OPEN AN ACCOUNT (You will receive a call & SMS from our end)
BUSINESS DESCRIPTION

No Description found

ADDRESS

Address: A-1311
Sun West Bank
Ashram Road
City: Ahmedabad,
State: Gujarat
Pincode: 380009
Phone: 079-48402525
Email: earumpharma@gmail.com
Website: www.earumpharma.com

LISTED AT

BSE

LEAD MANAGER

Hem Securities Ltd.

PROMOTERS

Bhumishth Narendrabhai Patel
Payal Bhumishth Patel

PROMOTER'S HOLDING

Total Share Capital

4319882

Offered to Public

1848000

Promoter's Holding (Pre-Issue)

100

Promoter's Holding (Post-Issue)

70.03
REGISTRAR

Bigshare Services Pvt Ltd
G 10 Left Wing Amruta Village
Opp: Yashoda Hospital
Raj Bhavan Road
Somajiguda
Hyderabad

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.